Article
Baseline amyloid deposition phenotypes inform the spatial distribution of early amyloid clearance with lecanemab in Alzheimer's disease.
European journal of nuclear medicine and molecular imaging - 1 Sept 2026
Dou Xiaofeng, Hu Daoyan, Wang Jing, Zhong Yan, Yu Congcong, Zhan Hongwei, Chen Yanxing, Zhou Rui, Zhang Xiaohui, Zhang Baorong, Zhou Jiong, Tian Mei, Zhang Hong, Yan Yaping, Jin Chentao
Abstract excerpt
OBJECTIVE: Lecanemab effectively reduces brain amyloid-β (Aβ) burden in early Alzheimer's disease (AD). However, Aβ deposition is spatially heterogeneous.The aim of this study is to test whether baseline β-amyloid (Aβ) deposition phenotype influences lecanemab-related Aβ clearance on Aβ-PET. METHODS: An Aβ Subtype and Stage Inference (SuStaIn) model was trained to identify Aβ progression phenotypes using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.